Large Cap Screen: March 2026 — S&P 100 Opportunities

1. Constellation Energy (CEG)

Ticker: CEG | Price: ~$291 | Market Cap: ~$78B

The Setup — Why NOW

CEG is the purest large-cap expression of the intersection of nuclear energy and AI infrastructure demand. The company finalized its $16.4B acquisition of Calpine (closed March 10, 2026), creating a 60-gigawatt "clean energy titan" combining the nation's largest nuclear fleet with Calpine's natural gas and geothermal assets. CEG now controls ~10% of U.S. clean energy output.

The stock pulled back ~10.9% from ~$323 to ~$291 on a $5B asset sale to LS Power — a tactical de-risking of the balance sheet post-Calpine, not a sign of fundamental deterioration. That pullback is the entry point.

Key demand driver: U.S. electricity demand is growing at the fastest pace since the 1960s–70s, driven by AI data center build-out. CEG's 20-year power purchase agreement with Microsoft for the restarted Crane Clean Energy Center (formerly Three Mile Island Unit 1) is the model being replicated across the portfolio. In March 2026, a Calpine subsidiary signed a 380 MW PPA with CyrusOne for Texas data center capacity.

Primary Catalyst (Next 3-6 Months)

• Earnings accretion from Calpine closes — management guided 20% EPS accretion by end of 2026.
• Additional hyperscaler PPA announcements — pipeline of data center deals being negotiated across nuclear and gas fleet.
• 2025 adjusted EPS of $9.39 is likely the floor; 2026 consensus projects 25% growth.

Key Risk

The $16.4B Calpine deal significantly increases leverage. If power prices or data center demand disappoint, the combined entity faces integration risk. Regulatory pushback on nuclear restart economics is a tail risk.

Valuation vs. History/Peers

• Consensus analyst target: $406.50 (14 Buys, 5 Holds, 0 Sells)
• Current price implies ~30% discount to consensus target
• Trades at roughly 30x 2026E EPS — elevated, but justified by contracted cash flow visibility and growth rate
• Peak was $402.95 in October 2025; current level represents a meaningful consolidation

VERDICT: OVERWEIGHT
The pullback is technically clean and fundamentally unjustified. Calpine integration and ongoing hyperscaler PPA deal flow make this a high-conviction name for the AI power infrastructure theme — without the valuation risk of Mag 7 tech.

2. CVS Health (CVS)

Ticker: CVS | Price: ~$75 | Market Cap: ~$91B

The Setup — Why NOW

CVS is one of the most oversold large-cap healthcare names in the S&P 100. After peaking above $110 in 2022, the stock spent 2023–2025 in a prolonged de-rating as Medicare Advantage (MA) cost ratios exploded across the industry. CVS/Aetna was among the hardest hit. The 52-week range of $58.35–$85.15 illustrates the severity of the discount.

The thesis is simple: the worst of the Medicare Advantage margin compression is priced in, and the reset is underway. CVS is strategically contracting its MA footprint (44 states → 43 states, 2,259 counties → 2,159 counties) to cut unprofitable members and improve the loss ratio. Q4 2025 earnings beat on both revenue ($105.7B, +8% YoY) and earnings, and management reaffirmed 2026 adjusted EPS guidance of $7.00–$7.20.

On March 12, 2026, Bernstein upgraded CVS to Outperform with a $94 price target, citing MA turnaround trajectory and the clearing of PBM regulatory overhang via FTC settlement. Cantor Fitzgerald also named CVS its top pick for Medicare Advantage exposure.

Primary Catalyst (Next 3-6 Months)

• Q1 2026 earnings — the first full clean quarter reflecting the repriced MA book; a clean beat would be the signal that the margin floor is in.
• PBM regulatory resolution — FTC settlement with Express Scripts/Cigna clears the air for the entire sector, reducing uncertainty on CVS Caremark.
• Medicare Advantage rate finalization for 2027 (CMS typically announces in April) — a favorable rate environment would be a direct earnings catalyst.

Key Risk

A 10% credit card interest rate cap proposal (affecting Aetna's health financing products), potential further MA rate pressure from CMS, and structural risks to the PBM model from ongoing congressional scrutiny. Balance sheet is stretched from the Aetna acquisition (2018) with ~$60B in debt.

Valuation vs. History/Peers

• Forward P/E of ~10x — vs. 5-year mean of ~13x and sector average ~15x
• Price/Sales of ~0.25x (deeply compressed)
• The stock trades as if the MA business is permanently impaired; the turnaround evidence says otherwise
• UnitedHealth Group trades at ~18x forward earnings; the discount to UNH is extreme

VERDICT: OVERWEIGHT
Classic "bad news fully priced" setup with a confirmed operational inflection. The Bernstein upgrade and Q4 beat provide fundamental validation. The MA business repricing is underway, not theoretical.

3. Wells Fargo (WFC)

Ticker: WFC | Price: ~$78 | Market Cap: ~$242B

The Setup — Why NOW

Wells Fargo is in the final stages of its multi-year regulatory rehabilitation. The OCC asset cap (the $1.95T balance sheet limit imposed in 2018 after the fake accounts scandal) was lifted in 2025 — the single most consequential regulatory event in the company's history. This frees WFC to grow its balance sheet competitively for the first time in seven years.

The stock sold off 4.6% in January 2026 after Q4 results sparked fears about NIM (net interest margin) pressure and severance charges from restructuring. That weakness is the entry point — the restructuring costs are one-time; the balance sheet unlock is permanent.

The $20B share repurchase authorization for 2026 is a direct capital return tailwind. WFC is buying back ~8% of its float at current prices.

Primary Catalyst (Next 3-6 Months)

• Q1 2026 earnings (mid-April) — first full quarter of unconstrained balance sheet growth; loan growth metrics will be the key signal.
• ROTCE trajectory — management targets 17–18% ROTCE. Current run rate is below this; each quarter of progress re-rates the stock.
• Rate cuts (2 expected in 2026) steepen the yield curve, directly benefiting NIM.
• Credit card rate cap proposal (capping at 10%) is a headwind to monitor closely — if it stalls in Congress (likely), the overhang clears.

Key Risk

The credit card interest rate cap proposal is the primary regulatory tail risk. A 10% cap would materially impair pre-tax earnings given WFC's 21% YoY credit card growth. Congressional passage probability appears low but is not zero in an election-adjacent year.

Valuation vs. History/Peers

• Trades at ~10x forward earnings vs. JPMorgan at ~13x and BAC at ~11x
• WFC has historically traded at a discount to JPM but the gap is now extreme given asset cap removal
• Price/Tangible Book ~1.7x — below peer average and well below WFC's own pre-scandal levels
• The ROTCE gap to target is the valuation gap; as it closes, the stock re-rates

VERDICT: OVERWEIGHT
The regulatory unlock is a multi-year earnings compounder. The Q4 selloff was a sentiment overshoot. Buyback yield + loan growth + ROTCE convergence makes this a high-quality financial re-rating story with a hard catalyst timeline.

4. Boeing (BA)

Ticker: BA | Price: ~$196 | Market Cap: ~$155B

The Setup — Why NOW

Boeing is the textbook "show me" story — the setup is compelling but execution has been the persistent failure. The stock has recovered ~34% year-over-year but sits 25% below its January 2026 high near $260 after a fresh wiring defect disclosure on undelivered 737 MAX aircraft in early March.

The fundamental thesis: Boeing has a $636B+ backlog, is the only U.S. wide-body manufacturer, and is targeting its first year of positive free cash flow since the 737 MAX groundings. Management guidance calls for $1B–$3B positive FCF in 2026, scaling to $6.8B in 2027 and $9–10B by 2028–2029 (Bernstein). 787 Dreamliner output is ramping from 7 to 10 units/month; 737 MAX is at 42/month, targeting 47 by mid-2026.

The March selloff is a buying opportunity IF the wiring issue is contained (early indications suggest it is — limited scope, no airworthiness impact).

Primary Catalyst (Next 3-6 Months)

• Q1 2026 earnings + FCF confirmation — the market needs to see the FCF positive trend hold.
• FAA 777-9 certification progression — cleared Phase 4 on March 17; full certification in 2026-2027 would unlock a new widebody product cycle.
• Spirit AeroSystems integration — successful absorption of the fuselage supplier reduces quality control risk structurally.
• Bernstein raised PT to $298, listing BA as a top idea for 2026.

Key Risk

Boeing's history is the risk. Another quality escape (like the March wiring issue) or another MAX production halt would be severely punished. The FAA is in active oversight mode. Defense division losses have been a consistent drag ($1.6B in program losses in Q2 2025 alone). Pension and debt obligations remain substantial.

Valuation vs. History/Peers

• Priced on a forward EV/FCF basis: the 2026 FCF of ~$2.3B puts the stock at ~50x FCF — expensive on near-term numbers, but 2027–2028 numbers bring that to a more reasonable 10–15x
• The investment is in the normalized FCF power, not current earnings
• Airbus trades at a meaningful premium on execution credibility — BA's valuation discount is warranted but excessive if production stabilizes

VERDICT: NEUTRAL (with a path to Overweight)
The setup is real, but Boeing has burned investors before. The March wiring issue is a yellow flag, not a red one — but it illustrates persistent quality risk. Wait for a clean Q1 print confirming FCF trajectory before adding. Current entry at ~$196 is reasonable for patient capital with a 12-18 month horizon.

5. Intel (INTC)

Ticker: INTC | Price: ~$44 | Market Cap: ~$220B

The Setup — Why NOW

Intel is the most controversial large-cap in semiconductors — genuinely binary, genuinely interesting. The stock has recovered ~30% YTD from depressed lows, driven by three converging catalysts:

1. Geopolitical TSMC risk: The Iran conflict and heightened Taiwan anxiety are prompting hyperscalers and the U.S. government to accelerate domestic foundry diversification. Intel's 18A process in Arizona/Oregon is the only credible domestic alternative to TSMC.
2. NVIDIA $5B strategic investment: NVIDIA committed $5B in Intel common stock (at $23.28/share) as part of a broad x86 co-development partnership. Regardless of foundry specifics, this de-risks Intel's competitive position and provides balance sheet credibility.
3. 18A process entering high-volume production: Intel 18A began HVM at Arizona and Oregon fabs in early 2026. Apple and NVIDIA are exploring it for specific dies (I/O and advanced packaging applications via EMIB).

The NVIDIA 18A foundry situation is nuanced: NVIDIA reportedly paused AI chip production testing on 18A, but CEO Tan clarified the $5B partnership is x86 co-development — not dependent on foundry. NVIDIA separately is exploring Intel 14A/18A for Feynman I/O dies.

Primary Catalyst (Next 3-6 Months)

• Q1 2026 earnings on April 23 — foundry revenue disclosures will be the market mover.
• Announcement of a committed external foundry customer for 18A (Apple, NVIDIA, or a hyperscaler) would be a material re-rating event.
• Taiwan escalation scenarios — any further geopolitical pressure on TSMC directly benefits INTC's domestic positioning.

Key Risk

The bear case is straightforward: 18A yield ramps slower than expected, NVIDIA's partnership remains an x86 software collaboration rather than a manufacturing relationship, and Intel burns cash while TSMC maintains its process lead. Consensus 12-month price target is only $38.31 — below current price — indicating most analysts are skeptical.

Valuation vs. History/Peers

• Trades at a premium to its recent depressed levels but discount to historical semiconductor multiples
• The valuation hinges entirely on foundry optionality — if 18A fails, the stock reverts to $25-30; if it succeeds and attracts a major customer, $60-70 is defensible
• Market cap at $220B implies moderate foundry success is priced in but not full realization

VERDICT: NEUTRAL
A speculative position for risk-tolerant capital. The geopolitical tailwind is real and durable; the foundry execution risk is also real. April 23 earnings are the next binary event. Not a core holding at current prices — wait for either a customer commitment on 18A or a pullback toward $38-40 for better risk/reward.

6. Pfizer (PFE)

Ticker: PFE | Price: ~$27 | Market Cap: ~$154B

The Setup — Why NOW

Pfizer is the S&P 100's most significant post-COVID value compression story. The stock has lost ~65% from its 2021 peak as COVID vaccine/antiviral revenue collapsed from $57B in 2022 to normalized levels. At $27 and 7.9x forward earnings (vs. the sector average 14.8x and PFE's own 5-year mean of 10.9x), the stock prices in near-permanent impairment.

The reality: Pfizer's non-COVID business is intact and growing, its pipeline is the deepest it has been in a decade, and management reaffirmed 2026 adjusted EPS guidance of $7.00–$7.20 after a solid Q4 2025 beat. The dividend yield at current prices is approaching 6.5% — one of the highest in the S&P 100.

Pfizer describes 2026 as "rich in key catalysts" with approximately 20 key pivotal study starts and multiple regulatory decisions across oncology, vaccines, and rare disease.

Primary Catalyst (Next 3-6 Months)

• Vepdegestrant (PROTAC ER degrader) FDA filing — met its Phase 3 primary endpoint in ER+ breast cancer; filing expected in 2026, potential approval in 2027. This is a potentially $5B+ peak sales drug in a validated commercial category.
• Padcev PDUFA for muscle-invasive bladder cancer — expanding into earlier-line treatment.
• Oncology portfolio execution — Elrexfio (multiple myeloma), Braftovi combinations; multiple data readouts 2026.
• Obesity pipeline — Metsera (through Pfizer's partnership) targeting up to 10 Phase III trials; this is optionality, not base case.

Key Risk

Pipeline execution risk is the dominant concern — Pfizer has historically disappointed on late-stage programs (e.g., the semaglutide competitor setback in 2023). Further COVID tailwind revenue erosion if antiviral sales decline faster than pipeline can offset. Patent cliffs on Eliquis (2026-2028) will pressure revenues.

Valuation vs. History/Peers

• 7.9x forward P/E vs. 14.8x sector average — the discount is extreme
• Dividend yield ~6.5% provides income support and a return floor
• EV/EBITDA at ~8x vs. Bristol-Myers (BMY) at ~9x and J&J at ~13x
• The stock is priced as if the pipeline is worthless; a single major approval proves that thesis wrong

VERDICT: OVERWEIGHT
The valuation floor is protected by a 6.5% dividend and $400B+ revenue base. The pipeline catalyst density in 2026 is high. The market is pricing in a no-growth scenario that doesn't reflect the business reality. This is a contrarian income + catalyst play with asymmetric risk/reward.

7. ExxonMobil (XOM)

Ticker: XOM | Price: ~$118 (estimated) | Market Cap: ~$470B

The Setup — Why NOW

ExxonMobil is not a contrarian pick — Energy is the leading sector YTD (+18%) — but the Iran conflict has created a structural, not cyclical, repricing of energy assets that the market is only partially acknowledging.

The Strait of Hormuz disruption is described by the IEA as "the largest supply disruption in the history of the global oil market." Even with Trump's pause on Iranian energy infrastructure strikes, Brent has held above $90-100 — a sustained level that unlocks significant free cash flow for XOM. At $100 Brent, ExxonMobil generates approximately $45-50B in operating cash flow annually.

The Pioneer Natural Resources acquisition (closed 2024) added ~1.3M BOE/day in low-cost Permian production. This is the highest-quality, lowest-break-even oil production in XOM's history.

Primary Catalyst (Next 3-6 Months)

• Oil price floor from Iran: Even with de-escalation, structural Hormuz risk keeps a $85-90 floor under Brent through 2026-2027.
• Pioneer integration synergies: Management guiding $2B+ in annual synergies by 2027; early execution appears on track.
• LNG export expansion — Golden Pass LNG (Sabine Pass, TX) expected to begin operations 2026, adding ~15 mtpa of export capacity; directly benefits from European energy diversification post-Iran.
• Share buybacks — XOM is buying back $20B/year at current prices.

Key Risk

The primary risk is oil price reversion. If U.S.-Iran tensions fully resolve and Hormuz reopens completely, Brent could fall to $70-75, meaningfully compressing XOM's cash generation. Downstream refining margins are already under pressure from high crude input costs. The energy sector has run hard — mean reversion is always a risk in commodities.

Valuation vs. History/Peers

• Trades at ~12-13x forward earnings — in-line with historical norms for XOM, not stretched
• EV/EBITDA ~8x vs. Chevron at ~9x
• Free cash flow yield of ~7-8% at $90+ Brent is exceptional for a $470B company
• BofA recently raised PT citing underpriced affiliate cash flows

VERDICT: OVERWEIGHT (risk-managed)
The Iran conflict has changed the risk/reward calculus for integrated energy majors for 2026. XOM's Permian production growth, LNG buildout, and disciplined capital allocation make it the preferred vehicle for the energy thesis. Scale back if oil pulls toward $80 or conflict resolution is confirmed.

8. Lockheed Martin (LMT)

Ticker: LMT | Price: ~$671 | Market Cap: ~$152B

The Setup — Why NOW

Lockheed Martin is near its all-time high (~$692), which might seem to disqualify it as a "beaten down" setup. The inclusion is justified by a different angle: valuation has lagged a dramatically improved fundamental environment.

The Iran war, ongoing Ukraine conflict, and Trump's proposed defense budget increase to $1.5T by 2027 (from $901B in 2026, a 76% increase) have structurally repriced the defense sector. However, LMT has lagged GE Aerospace (+87% in 2025) and RTX (+50% in 2025) — partly due to a disappointing Q2 2025 earnings miss (~$1.6B in program losses, 78% EPS miss).

The Q2 miss was program-specific (F-35 production and supply chain issues). The backlog remains massive at $165B+, and the F-35 program — regardless of production headaches — is not at risk of cancellation. The $3B dividend payout in 2026 and consistent buybacks provide a return floor.

The proposed $200B+ Pentagon supplemental request tied to Iran is the near-term catalyst the analyst consensus is underweighting.

Primary Catalyst (Next 3-6 Months)

• Pentagon supplemental appropriations related to Iran conflict — Lockheed's missile and air defense systems (HIMARS, THAAD, PAC-3) are direct beneficiaries.
• F-35 production normalization — Q1 2026 earnings will be watched for evidence that the Q2 2025 program losses were contained.
• NATO spending increases — 32 NATO members at or above 2% GDP defense spending threshold for first time; Lockheed is the dominant supplier.
• Golden Dome missile defense initiative catalyst — LMT named as a primary contractor for next-generation layered defense.

Key Risk

Program execution is the endemic risk — Lockheed has a history of cost overruns on fixed-price development contracts. Analyst consensus is "Hold" with a $659 average target (below current), suggesting the run may be mature in the near term. Any normalization of the Iran conflict removes the near-term budget catalyst.

Valuation vs. History/Peers

• Trades at ~17x forward earnings — at the upper end of LMT's historical range
• Dividend yield ~2.5% provides income support
• RTX at ~22x and GE Aerospace at ~32x make LMT look modestly valued within defense peers
• The earnings power is real but the program risk makes full-price commitment uncomfortable

VERDICT: NEUTRAL
LMT offers defense budget tailwinds and a genuine geopolitical catalyst, but it's near all-time highs and analyst consensus is unconvinced. Better entry on pullbacks toward $600-620. RTX remains the preferred defense holding on program execution track record.